Polycystic Ovary Syndrome
Conditions
Keywords
Exercise therapy, Adipose tissue, Mitochondria, Oxidative Phosphorylation
Brief summary
The primary aim of this trial is to investigate adipose tissue function in women with and without polycystic ovary syndrome (PCOS). PCOS is a common endocrine disorder in young women. The pathogenesis behind PCOS is complex and only partly understood, and deeper mechanistic insight is needed. Insulin resistance is a central feature of PCOS, and recent studies have suggested that this is linked to aberrant adipose tissue function. Exercise training has been found to improve the symptoms in PCOS, but we need more knowledge about why. While processes involved in skeletal muscle oxidative remodeling are well described, it is to a large extent unknown whether the oxidative capacity of human adipose tissue is modified by endurance training. The women included in this study will be matched (for body mass index, body weight, and age) to participants in another study. This will enable the investigators to do a comparison between cases (women with PCOS) and controls (women without PCOS) at baseline, and to assess the responses to exercise training in adipose tissue.
Interventions
Treadmill running/walking with 10 minutes warm-up at 60-70% of maximum heart rate, 4x4 minute intervals at 90-95% of maximum heart rate separated by 3-minutes active pauses at 60-70% of maximum heart rate, and 3 minutes cool-down.
Treadmill running/walking with 10 minutes warm-up at 60-70% of maximum heart rate, ten 1-minute intervals at maximal intensity (that can be performed for one minute), separated by 1-minutes active pauses at 60-70% of maximum heart rate, and 3 minutes cool-down.
Sponsors
St. Olavs Hospital
Liverpool John Moores University
Australian Catholic University
Norwegian University of Science and Technology
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
No
Inclusion criteria
* eumenorrheic * matching PCOC group in IMPROV-IT study (NCT02419482) * Living nearby St Olavs Hospital, Trondheim, Norway
Exclusion criteria
* Signs of hyperandrogenism * Regular high intensity endurance (two or more times per week of vigorous exercise). * Concurrent treatments (insulin sensitizers or drugs known to affect gonadotropin or ovulation, with a wash out period of 1 months prior to inclusion). * On-going pregnancy * Hormonal contraception * Breastfeeding within 24 weeks
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| mitochondrial oxidative phosphorylation capacity | 16 weeks | assessed with high resolution respirometry |
| production of reactive oxygen species | 16 weeks | assessed with high resolution respirometry |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Total cholesterol in blood | 16 weeks | — |
| HDL cholesterol in blood | 16 weeks | — |
| LDL cholesterol in blood | 16 weeks | — |
| blood glucose | 16 weeks | — |
| blood insulin | 16 weeks | — |
| Adipokine secretion | 16 weeks | — |
| lipid droplet size in adipocytes | 16 weeks | — |
| Whole-body fat oxydation rate | 16 weeks | — |
| endothelial function | 16 weeks | measured by flow-mediated dilatation of the brachial artery |
| Whole-body peak oxygen uptake | 16 weeks | — |
| Adipokine gene expression | 16 weeks | — |
| Total protein abundance in adipose tissue | 16 weeks | quantified using standard Western Blot method |
| blood markers of cardiometabolic health | 16 weeks | — |
| Body composition | 16 weeks | assessed by impedance scale (InBody) |
| blood pressure | 16 weeks | — |
| Glycosylated Hemoglobin (HbA1c) in blood | 16 weeks | — |
| Insulin sensitivity | 16 weeks | 2h oral glucose tolerance test (OGGT) |
| Intima media thickness | 16 weeks | measured by ultrasound |
Countries
Australia, Norway
Outcome results
None listed